Breast

Protocols

Adjuvant
Locally Advanced
Advanced

Adjuvant

UBRAJABEAI

Treatment of Adjuvant Breast Cancer using Abemaciclib and Aromatase Inhibitor With or Without LHRH Agonist

UBRAJABET

Treatment of Adjuvant Breast Cancer using Abemaciclib and Tamoxifen With or Without LHRH Agonist

BRAJAC

Adjuvant Therapy for Breast Cancer Using DOXOrubicin and Cyclophosphamide

BRAJACT

Neoadjuvant or Adjuvant Therapy for Breast Cancer using DOXOrubicin and Cyclophosphamide followed by PACLitaxel

BRAJACTG

Neoadjuvant or Adjuvant Therapy for Breast Cancer using Dose Dense Therapy: DOXOrubicin and Cyclophosphamide followed by PACLitaxel

BRAJACTT

Neoadjuvant or Adjuvant Therapy for Breast Cancer using DOXOrubicin and Cyclophosphamide followed by PACLitaxel and Trastuzumab

BRAJACTTG

Neoadjuvant or Adjuvant Therapy for Breast Cancer Using Dose Dense Therapy: DOXOrubicin and Cyclophosphamide Followed by PACLitaxel and Trastuzumab

BRAJACTW

Neoadjuvant or Adjuvant therapy for Early Breast Cancer Using DOXOrubicin and Cyclophosphamide Followed by Weekly PACLitaxel

BRAJANAS

Neoadjuvant or Adjuvant Therapy for Breast Cancer using Anastrozole in Postmenopausal Women

BRAJCAP

Therapy of Adjuvant Breast Cancer using Capecitabine

BRAJCMFPO (deleted 01 Sep 2023)

Adjuvant Therapy for High-Risk Breast Cancer using Cyclophosphamide (oral), Methotrexate and Fluorouracil

BRAJDAC

Neoadjuvant or Adjuvant Therapy for Breast Cancer using Cyclophosphamide, DOXOrubicin and DOCEtaxel

BRAJDC

Adjuvant Therapy for Breast Cancer Using DOCEtaxel and Cyclophosphamide

BRAJDCARBT

Neoadjuvant or Adjuvant Therapy for Breast Cancer Using DOCEtaxel, CARBOplatin, and Trastuzumab

BRAJEXE

Neoadjuvant or Adjuvant Therapy for Breast Cancer using Exemestane in Postmenopausal Women

BRAJFEC

Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide

BRAJFECD

Neoadjuvant or Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin, Cyclophosphamide and DOCEtaxel

BRAJFECDT

Neoadjuvant or Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide Followed by DOCEtaxel and Trastuzumab

UBRAJKAD

Adjuvant Therapy for Breast Cancer using Trastuzumab Emtansine (KADCYLA)

BRAJLET

Neoadjuvant or Adjuvant Therapy for Breast Cancer using Letrozole in Postmenopausal Women

BRAJLHRHAI

Neoadjuvant or Adjuvant Ovarian Suppression and Aromatase Inhibitor in Premenopausal Women with High Risk Early Stage Breast Cancer

BRAJLHRHT

Neoadjuvant or Adjuvant Therapy for Breast Cancer Using a LHRH Agonist and Tamoxifen

UBRAJOLA

Treatment of BRCA-Mutated High-Risk Early Breast Cancer using Olaparib

BRAJPAM

Adjuvant Therapy for Breast Cancer in Post-menopausal Women Using Pamidronate

BRAJPEM

Adjuvant Treatment of Resected Triple Negative Breast Cancer using Pembrolizumab

BRAJPN

Alternative Adjuvant Therapy for Breast Cancer using PACLitaxel NAB (ABRAXANE)

BRAJPNCT

Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer using PACLitaxel NAB (ABRAXANE), CARBOplatin and Trastuzumab

BRAJPNT

Alternative Adjuvant Therapy for Breast Cancer using PACLitaxel NAB (ABRAXANE) and Trastuzumab

BRAJTAM

Neoadjuvant or Adjuvant Therapy for Breast Cancer Using Tamoxifen

BRAJTDC

Neoadjuvant or Adjuvant Therapy for Breast Cancer Using Trastuzumab, DOCEtaxel and Cyclophosphamide

BRAJTR

Adjuvant Therapy for Breast Cancer Using Trastuzumab following the Completion of Chemotherapy (Sequential)

BRAJTTW

Adjuvant Therapy for Breast Cancer Using Weekly PACLitaxel and Trastuzumab

BRAJZOL2

Adjuvant Therapy for Breast Cancer in Post-Menopausal Women Using 3-Monthly Zoledronic Acid

BRAJZOL5

Adjuvant Therapy for Breast Cancer in post-menopausal Women Using 6-Monthly Zoledronic Acid

Top

Locally Advanced

BRAJPEM

Adjuvant Treatment of Resected Triple Negative Breast Cancer using Pembrolizumab

(SEE UNDER ADJUVANT SECTION)

BRLAACD

Treatment of Locally Advanced Breast Cancer Using DOXOrubicin and Cyclophosphamide Followed by DOCEtaxel

BRLAACDT

Treatment of Locally Advanced Breast Cancer Using DOXOrubicin and Cyclophosphamide Followed by DOCEtaxel and Trastuzumab

BRLACPNAC

Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide

BRLACPNACG

Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using Dose Dense Therapy: CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide

BRLACTWAC

NEOAdjuvant Therapy for Triple Negative Breast Cancer Using Carboplatin and Weekly PACLitaxel Followed by DOXOrubicin and Cyclophosphamide

BRLACTWACG

NEOAdjuvant Therapy for Triple Negative Breast Cancer using Dose Dense Therapy: Carboplatin and Weekly PACLitaxel Followed by DOXOrubicin and Cyclophosphamide

BRLAPNAC

Alternative NEOAdjuvant Therapy for Locally Advanced Breast Cancer using PACLitaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide

BRLAPNACG

Alternative NEOAdjuvant Therapy for Breast Cancer using Dose Dense Therapy: PACLitaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide

BRLATACG

NEOAdjuvant Therapy for Breast Cancer Using Dose Dense Therapy: PACLitaxel Followed by DOXOrubicin and Cyclophosphamide

BRLATWAC

NEOAdjuvant Therapy for Locally Advanced Breast Cancer Using Weekly PACLitaxel Followed by DOXOrubicin and Cyclophosphamide

BRPCTAC

NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab with CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide

BRPCWTAC

NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab, Weekly CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide

Top

Advanced

BRAVA7

Palliative Therapy for Metastatic Breast Cancer Using Weekly DOXOrubicin

BRAVAC

Palliative Therapy for Metastatic Breast Cancer Using DOXOrubicin and Cyclophosphamide

BRAVABR

Palliative Therapy for Metastatic Breast Cancer using PACLitaxel NAB (ABRAXANE)

BRAVANAS

Palliative Therapy for Metastatic Breast Cancer Using Anastrozole

BRAVCAP

Therapy for Metastatic Breast Cancer Using Capecitabine

BRAVCLOD

For Therapy of Bone Metastases in Breast Cancer Using Oral Clodronate

BRAVCMF

Palliative Therapy for Advanced Breast Cancer Using Cyclophosphamide, Methotrexate and Fluorouracil

BRAVCMPO

Palliative Therapy for Metastatic Breast Cancer Using Metronomic Low-Dose Oral Cyclophosphamide and Methotrexate

BRAVDOC

Palliative Therapy for Metastatic Breast Cancer Using DOCEtaxel

BRAVDOC7

Palliative Therapy for Metastatic Breast Cancer Using Weekly Docetaxel

BRAVENH

Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Deruxtecan (ENHERTU)

BRAVERIB

Palliative Therapy for Metastatic Breast Cancer Using eriBULin

BRAVEVEX

Therapy for Advanced Breast Cancer Using Everolimus and Exemestane

BRAVEXE

Palliative Therapy for Advanced Breast Cancer Using Exemestane

BRAVGEM

Palliative Therapy for Metastatic Breast Cancer Using Gemcitabine

BRAVGEMD

Palliative Therapy for Metastatic Breast Cancer Using Gemcitabine and DOCEtaxel

BRAVGEMP

Palliative Therapy for Metastatic Breast Cancer Using CISplatin and Gemcitabine

BRAVGEMT

Palliative Therapy for Metastatic Breast Cancer Using Gemcitabine and PACLitaxel

BRAVHDMTX

Treatment of Meningeal Disease using High-Dose Methotrexate with Leucovorin Rescue

BRAVHDMTX Protocol

BRAVKAD

Palliative Therapy for Metastatic Breast Cancer Using Trastuzumab Emtansine (KADCYLA)

BRAVLCAP

Therapy for Metastatic Breast Cancer Using Capecitabine and Lapatinib

BRAVLET

Palliative Therapy for Advanced Breast Cancer Using Letrozole

BRAVLHRHAI (previously BRAVLHRHA)

Therapy for Advanced Breast Cancer Using a LHRH Agonist and an Aromatase Inhibitor

BRAVLHRHT

Palliative Therapy for Breast Cancer Using a LHRH agonist and tamoxifen

BRAVMEG

Palliative Therapy for Advanced Breast Cancer Using Megestrol

BRAVNAV

Palliative Therapy for Symptomatic Metastatic Breast Cancer Using Vinorelbine

BRAVPALAI

Therapy of Advanced Breast Cancer Using Palbociclib and Aromatase Inhibitor With or Without LHRH Agonist

BRAVPAM

Prevention of Skeletal Related Events Secondary to Breast Cancer Metastases Using Pamidronate

BRAVPBFLV

Therapy of Advanced Breast Cancer using Palbociclib and Fulvestrant With or Without LHRH Agonist

BRAVPGC

Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab, Gemcitabine, and CARBOplatin

BRAVPP

Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab with PACLitaxel

BRAVPPN

Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab and PACLitaxel NAB (ABRAXANE)

BRAVPTRAD

Palliative Therapy for Metastatic Breast Cancer Using PERTuzumab, Trastuzumab, and DOCEtaxel as First-Line Treatment for Advanced Breast Cancer

BRAVPTRAT

Palliative Therapy for Metastatic Breast Cancer Using PERTuzumab, Trastuzumab, and PACLitaxel as First-Line Treatment for Advanced Breast Cancer

BRAVPTRVIN

Palliative Therapy for Metastatic Breast Cancer using PERTuzumab, Trastuzumab, and Vinorelbine as First-Line Treatment for Advanced Breast Cancer

BRAVRBFLV

Therapy of Advanced Breast Cancer using Ribociclib and Fulvestrant With or Without LHRH Agonist

BRAVRIBAI

Therapy of Advanced Breast Cancer Using Ribociclib and Aromatase Inhibitor With or Without LHRH Agonist

BRAVSG

Palliative Therapy for Metastatic Triple Negative Breast Cancer using Sacituzumab Govitecan

BRAVTAM

Palliative Therapy for Breast Cancer Using Tamoxifen

BRAVTAX

Palliative Therapy for Metastatic Breast Cancer Using PACLitaxel

BRAVTCAP

Palliative Therapy for Metastatic Breast Cancer Using Trastuzumab and Capecitabine

BRAVTEST

Palliative Therapy for Metastatic Breast Cancer Using Testosterone Enanthate

BRAVTPCARB (deleted 01 Jan 2021)

BRAVTR

Palliative Therapy for Metastatic Breast Cancer Using Trastuzumab

UBRAVTTCAP

Palliative Therapy for Metastatic Breast Cancer using Trastuzumab, Tucatinib, and Capecitabine

BRAVTW

Palliative Therapy for Metastatic Breast Cancer Using Weekly PACLitaxel (3 Weeks Out of 4 Weeks Schedule)

BRAVZOL

Treatment of Acute Bone Pain Secondary to Breast Cancer Metastases Using IV Zoledronic Acid

Funding Algorithm

The funding algorithm provides information on what anti-cancer systemic therapy treatments are covered on the BC Cancer Benefit Drug List (formulary). It may not be a complete list of all treatment options that may be available and recommended by the treating physician.

The information contained in these documents is a statement of consensus of BC Cancer professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is at your own risk and is subject to BC Cancer's terms of use.

Tab Heading